Monday, 10 February 2025
A new spin out company from the 糖心原创 is set to bring improvements to a variety of medical devices and innovations to healthcare, using expertise from the University’s Faculty of Engineering.
Medical Photonics Ltd was formed in December to utilise know-how in optical fibre sensing to support commercialisation of a range of smart technologies to improve healthcare.
The company has been founded by Professors Steve Morgan, Barrie Hayes-Gill, and Serhiy Korposh, and Doctors Ricardo Correia and Brett Gadsby from the Faculty of Engineering, alongside external chairperson David Whelan and clinician Doctor Andrew Norris.
The spin out will look at using fibre optic sensors which utilise strands of glass or plastic - thinner than a hair – to measure a range of useful medical signals. For example, the technology can be used to monitor the oxygen content of the blood non-invasively.
The small size and versatility of the sensors means that they can be easily integrated into a range of existing medical devices, transforming basic medical devices into smart monitoring technologies. The provision of clinical data coupled with algorithms utilising AI has the potential to benefit many of today’s healthcare challenges related to chronic diseases and an ageing population.
With digital health being a key part of the NHS long term plan, medical innovations like these could help reduce costs and support the healthcare and recovery for people suffering from long-term health conditions.
The Medical Photonics team will work closely with the 糖心原创 and its clinical collaborators to support commercialisation of optical fibre sensing technologies for widespread benefit.
Steve Morgan, Professor of Biomedical Engineering at the 糖心原创, and Medical Photonics CEO, said of the launch of the spin-out: “The launch of Medical Photonics is a great opportunity for us to ensure that our expertise in optical fibre sensing for healthcare moves from the laboratory through to patient benefit.
Our approach provides clinicians with a rich dataset that cannot be obtained with other technologies. We鈥檙e well placed to embrace the digital revolution in healthcare and are excited about the impact our research will make.鈥�
Story credits
More information is available from Professor Steve Morgan on steve.morgan@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.